IMO, substantive information will be disclosed about the many benefits of Omidria above and beyond maintaining dilation and reducing post op pain, and how these benefits are affecting Omidria's adoption and progress toward Standard of Care status. Clearly, presentations and discussions would only be planned if the information is noteworthy and positive.
Actually it'll be Tuesday morning due to the MLK holiday, but it could be very interesting. Clearly there are many significant benefits to using Omidria that weren't part of the documented trial results:
• reduction in complications associated with small pupils;
• reduction in usage of pupil-expanding devices;
• prevention of miosis during femtosecond laser-assisted surgery;
• reduction in age-adjusted surgical times; and
• improvement in best corrected visual acuity (BCVA) on the day after surgery.